| Autor: |
Martz CA; Department of Internal Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.; Department of Medicine, Boston Children's Hospital, Boston, Massachusetts, USA., Jarbeau JF; Department of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA., Castillo JJ; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Fisher DC; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Nohria A; Cardio-Oncology Program, Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA. |
| Abstrakt: |
Competing Interests: Dr. Castillo has received research support and honoraria from Abbvie, Beigene, Janssen, Pharmacyclics, Roche, and TG Therapeutics. Dr. Nohria has received research support from Amgen and the Gelb Master Clinician Award and the Catherine Geoff Fitch Fund; and is a consultant for Takeda Oncology and AstraZeneca. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. |
